From GlobeNewswire:

CervoMed Inc. (NASDAQ: CRVO) will provide a corporate update at the Emerging Growth Conference 66 on January 11th, 2024 at 11:25 AM ET. A live webcast of the presentation and accompanying slides will be accessible, with a replay available following the event. CervoMed Inc. is a clinical-stage biotechnology company focused on developing treatments for age-related neurologic disorders. They are currently developing neflamapimod, an investigational orally administered small molecule brain penetrant that inhibits p38MAP kinase alpha (p38a). Neflamapimod is being evaluated in a Phase 2b study in patients with dementia with Lewy bodies (DLB).



Read more: CervoMed to Participate in the Emerging Growth Conference